Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy

Research output: Contribution to journalArticle

Authors

Institutes & Expert groups

  • CERN - Conseil Européen pour la Recherche Nucléaire
  • KUL - Katholieke Universiteit Leuven
  • JGU - Johannes Gutenberg University Mainz - Institut für Physik
  • University of Manchester

Documents & links

DOI

Abstract

Targeted radionuclide therapy (TRNT) has proven to be successful in oncology over the last decade (1–5). In TRNT a radionuclide is linked to a molecule that selectively binds to over-expressed receptors of cancer cells, allowing for a targeted approach in cancer therapy. Accumulation of the radiopharmaceutical in tumor tissue delivers toxic levels of radiation directly to the malicious tumor cells minimizing dose given to healthy tissue.

Details

Original languageEnglish
Article number675221
Pages (from-to)1-9
Number of pages9
JournalFrontiers in Medicine
Volume8
DOIs
Publication statusPublished - 19 Jul 2021

Keywords

  • Radiolanthanides, Samarium-153, Theranostics, Targeted radionuclide therapy, Cancer, Nuclear medicine, Mass separated radionuclides, Resonant laser ionization

ID: 7174671